secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001683168-24-003178
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio Pharmaceuticals Q1 2024 net loss narrows to $2.2M; cash at $6.5M
---------------------------------------------------------------------

- Cash of $6.5M at March 31, 2024, down from $8.5M at Dec 31, 2023.
- Net loss of $2.2M for Q1 2024 vs $3.6M in prior-year quarter; R&D expenses fell 46% to $1.1M.
- Phase 1b trial of PH-762 in skin cancers has enrolled 3 patients at 4 U.S. sites.
- USPTO granted patents for INTASYL compounds RXI-185 and RXI-231 targeting age-related skin disorders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000168316824003178/0001683168-24-003178-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000168316824003178/phio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-003178

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer